SCD-CARRE

• Research type

  Research Study

• Full title

  Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)

• IRAS ID

  276528

• Contact name

  J Simon R Gibbs

• Contact email

  s.gibbs@imperial.ac.uk

• Sponsor organisation

  Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute

• Clinicaltrials.gov Identifier

  NCT04084080

• Duration of Study in the UK

  5 years, 3 months, 6 days

• Research summary

  The SCD-CARRE trial is a Phase 3, prospective, randomized, multicentre, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult sickle cell disease (SCD) patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion centre (this term includes urgent pain treatment with infusion of opiates, IV fluids which is arranged electively/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.

• REC name

  Wales REC 5

• REC reference

  21/WA/0206

• Date of REC Opinion

  1 Dec 2021

• REC opinion

  Further Information Favourable Opinion